Search Within

Martin Stuart Tallman

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (74)
  2. Journal Article (61)
  3. Research Letter (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Review (1)
Groups
  1. Adult Leukemia (140)
  2. Center for Hematologic Malignancies (140)
  3. Department of Medicine (140)
  4. GSK Faculty (140)
  5. Hematologic Malignancies, Division of (140)
  6. Human Oncology and Pathogenesis Program (140)

More Groups

People
  1. Ross Levine (131)
  2. Omar Abdel-Wahab (51)
  3. Maria Arcila (30)
  4. Eytan Stein (29)
  5. Minal Patel (24)
  6. Raajit Rampal (24)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (7)
  4. 2021 (7)
  5. 2020 (13)
  6. 2019 (11)

More Years

Publications
  1. Blood (70)
  2. Haematologica (8)
  3. Blood Advances (6)
  4. Leukemia Research (6)
  5. Cancer Research (5)
  6. Cancer Discovery (4)

More Publications

Publishers
  1. American Society of Hematology (76)
  2. Nature Publishing Group (14)
  3. American Association for Cancer Research (9)
  4. Ferrata Storti Foundation (8)
  5. Cell Press (6)
  6. Elsevier Ltd (6)

More Publishers

Results (140)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
    Journal Article

    Xiao, W.; Goldberg, A. D.; Famulare, C. A.; Devlin, S. M.; Nguyen, N. T.; Sim, S.; Kabel, C. C.; Patel, M. A.; McGovern, E. M.; Patel, A.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML
    Journal Article

    Duy, C.; Teater, M.; Garrett-Bakelman, F. E.; Lee, T. C.; Meydan, C.; Glass, J. L.; Li, M.; Hellmuth, J. C.; Mohammad, H. P.; Smitheman, K. N.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: A subset analysis from ECOG-ACRIN 1900
    Journal Article

    Fernandez, H. F.; Sun, Z.; Litzow, M. R.; Luger, S. M.; Paietta, E.; Racevskis, J.; Levine, R. L.; Patel, J. P.; Abdel-Wahab, O.; Ketterling, R. P.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
    Journal Article

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Pollyea, D. A.; Stone, R. M.; Altman, J. K.; Roboz, G. J.; Patel, M. R.; Collins, R.; Flinn, I. W.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial
    Meeting Abstract

    Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • AML with mutations in IDH1 and DNMT3A exhibits a distinct epigenetic signature with poorer overall survival
    Meeting Abstract

    Ahr, K.; Famulare, C.; Koche, R.; Spitzer, B.; Levine, R. L.; Tallman, M. S.; Goldberg, A. D.; Stein, E. M.; Glass, J. L.
    Blood (2018)

    Fulltext@MSK | Save
  • Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
    Meeting Abstract

    Bolton, K.; Ptashkin, R.; Braunstein, L.; Kelly, D.; Devlin, S. M.; Coombs, C. C.; Moarii, M.; Patel, M.; Bernard, E.; Berthon, A.; more...
    Blood (2018)

    Fulltext@MSK | Save